Ulcerative Colitis Research Studies

Ulcerative colitis (UC) is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in the lining of the large intestine.

Enrolling: Yes

Principle Investigator: Monika Fischer, MD

Duration: 17 Months (Approx. 7 clinic visits + two colonoscopies)

Patient Population:  Adult patients with mild to moderate Ulcerative Colitis

Study Intervention:  SER-287 Investigational Microbiome Drug

Possibility of Placebo:  1 in 3

Enrolling: Will Begin Enrollment near the end of 2020

Principle Investigator: Sashidhar Sagi, MD

Duration: 15 months (with the option of an additional 2 years of treatment after)

Patient Population:  Adult patients with moderate to severe Ulcerative Colitis

Study Intervention:  Guselkumab

Possibility of Placebo: 1 in 3

Enrolling: On Hold

Principle Investigator:  Matthew Bohm, DO

Duration:  All bio-specimen collections and chart reviews will continue until 2026

Patient Population: Any patient with either Crohn’s Disease or Ulcerative Colitis

Study Intervention:  Medical chart reviews and biological specimen collection.

Enrolling: Yes

Principle Investigator:  Monika Fischer, MD

Duration:  12 months

Patient Population: Any patient with Ulcerative Colitis starting Tofacitinib (Xeljanz) for the first time as part of their standard treatment for UC.

Study Intervention:  Medical chart review and e-mail patient questionnaires (Enrollment and participation is done via phone.)